Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K C Marsh

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|March 28, 1995
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humansD J Kempf, K C Marsh, J F Denissen, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1991
Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 proteaseD J Kempf, K C Marsh, D A Paul, et al.
Alzheimer Disease and Associated Disorders|January 1, 1995
Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective propertiesS P Arneric, J P Sullivan, M W Decker, et al.
Journal of Medicinal Chemistry|October 29, 2000
Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 1. Identification of an additional binding pocket based on an anilino diaryl sulfide leadG Liu, J T Link, Z Pei, et al.
Bioorganic & Medicinal Chemistry Letters|February 6, 1999
Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligandsX Chen, D J Kempf, H L Sham, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 1, 1990
Metabolism and disposition of clarithromycin in manJ L Ferrero, B A Bopp, K C Marsh, et al.
Life Sciences|November 24, 1998
The effects of diminishing albumin binding to some Endothelin receptor antagonistsB G Szczepankiewicz, R B Bal, T W von Geldern, et al.
Journal of Medicinal Chemistry|February 16, 1996
Azole endothelin antagonists. 3. Using delta log P as a tool to improve absorptionT W von Geldern, D J Hoffman, J A Kester, et al.
Journal of Medicinal Chemistry|September 10, 1999
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivityT W von Geldern, A S Tasker, B K Sorensen, et al.
Journal of Medicinal Chemistry|January 31, 1997
Potent and selective non-benzodioxole-containing endothelin-A receptor antagonistsA S Tasker, B K Sorensen, H S Jae, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Proceedings of the National Academy of Sciences of the United States of America|March 28, 1995
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humansD J Kempf, K C Marsh, J F Denissen, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1991
Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 proteaseD J Kempf, K C Marsh, D A Paul, et al.
Alzheimer Disease and Associated Disorders|January 1, 1995
Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective propertiesS P Arneric, J P Sullivan, M W Decker, et al.
Journal of Medicinal Chemistry|October 29, 2000
Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 1. Identification of an additional binding pocket based on an anilino diaryl sulfide leadG Liu, J T Link, Z Pei, et al.
Bioorganic & Medicinal Chemistry Letters|February 6, 1999
Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligandsX Chen, D J Kempf, H L Sham, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 1, 1990
Metabolism and disposition of clarithromycin in manJ L Ferrero, B A Bopp, K C Marsh, et al.
Life Sciences|November 24, 1998
The effects of diminishing albumin binding to some Endothelin receptor antagonistsB G Szczepankiewicz, R B Bal, T W von Geldern, et al.
Journal of Medicinal Chemistry|February 16, 1996
Azole endothelin antagonists. 3. Using delta log P as a tool to improve absorptionT W von Geldern, D J Hoffman, J A Kester, et al.
Journal of Medicinal Chemistry|September 10, 1999
Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivityT W von Geldern, A S Tasker, B K Sorensen, et al.
Journal of Medicinal Chemistry|January 31, 1997
Potent and selective non-benzodioxole-containing endothelin-A receptor antagonistsA S Tasker, B K Sorensen, H S Jae, et al.
Pageof 5